Structural reorganization of SHP2 by oncogenic mutations and implications for oncoprotein resistance to allosteric inhibition-Reference-Cited by-同舟云学术

Structural reorganization of SHP2 by oncogenic mutations and implications for oncoprotein resistance to allosteric inhibition

Published:2018-10-30 Issue:1 Volume:9 Page:
ISSN:2041-1723
Container-title:Nature Communications
language:en
Short-container-title:Nat Commun

Author:

LaRochelle Jonathan R.^ORCID,Fodor Michelle,Vemulapalli Vidyasiri,Mohseni Morvarid^ORCID,Wang Ping,Stams Travis,LaMarche Matthew J.,Chopra Rajiv,Acker Michael G.,Blacklow Stephen C.^ORCID

Publisher

Springer Science and Business Media LLC

Subject

General Physics and Astronomy,General Biochemistry, Genetics and Molecular Biology,General Chemistry

Link

http://www.nature.com/articles/s41467-018-06823-9.pdf

Reference30 articles.

1. Chan, G., Kalaitzidis, D. & Neel, B. G. The tyrosine phosphatase Shp2 (PTPN11) in cancer. Cancer Metastasis Rev. 27, 179–192 (2008).

2. Li, J. et al. PD-1/SHP-2 inhibits Tc1/Th1 phenotypic responses and the activation of T cells in the tumor microenvironment. Cancer Res. 75, 508–518 (2015).

3. Noguchi, T., Matozaki, T., Horita, K., Fujioka, Y. & Kasuga, M. Role of SH-PTP2, a protein-tyrosine phosphatase with Src homology 2 domains, in insulin-stimulated Ras activation. Mol. Cell Biol. 14, 6674–6682 (1994).

4. Zhang, J., Zhang, F. & Niu, R. Functions of Shp2 in cancer. J. Cell Mol. Med. 19, 2075–2083 (2015).

5. Tartaglia, M. et al. Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndrome. Nat. Genet. 29, 465–468 (2001).

Cited by 121 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeting the RAS upstream and downstream signaling pathway for cancer treatment;European Journal of Pharmacology;2024-09

2. Advances in SHP2 tunnel allosteric inhibitors and bifunctional molecules;European Journal of Medicinal Chemistry;2024-09

3. Bivalent target-binding bioPROTACs induce potent degradation of oncogenic SHP2;Journal of Biological Chemistry;2024-09

4. Discovery of TK-642 as a highly potent, selective, orally bioavailable pyrazolopyrazine-based allosteric SHP2 inhibitor;Acta Pharmaceutica Sinica B;2024-08

5. SHP2 mutations promote glycolysis and inhibit apoptosis via PKM2/hnRNPK signaling in colorectal cancer;iScience;2024-08